GRAIL, Inc. (NASDAQ:GRAL) Receives Average Rating of “Hold” from Brokerages

Shares of GRAIL, Inc. (NASDAQ:GRAL) have been assigned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $68.6250.

A number of research analysts have recently commented on GRAL shares. Mizuho initiated coverage on GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective on the stock. Wall Street Zen lowered GRAIL from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Piper Sandler began coverage on GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $54.00 target price for the company. TD Cowen upgraded GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price target on the stock in a report on Wednesday, March 18th. Finally, Guggenheim lowered their price target on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a report on Monday, March 30th.

GRAIL Price Performance

Shares of NASDAQ GRAL opened at $55.66 on Tuesday. GRAIL has a one year low of $29.95 and a one year high of $118.84. The business’s 50-day moving average price is $50.32 and its two-hundred day moving average price is $78.86. The company has a market capitalization of $2.39 billion, a P/E ratio of -4.98 and a beta of 3.03.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The firm had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. On average, equities analysts anticipate that GRAIL will post -11.82 EPS for the current year.

Insider Buying and Selling at GRAIL

In other GRAIL news, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the transaction, the president owned 371,216 shares in the company, valued at $18,531,102.72. This trade represents a 14.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Ragusa sold 123,502 shares of the stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the transaction, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 310,267 shares of company stock worth $15,485,396 over the last 90 days.

Hedge Funds Weigh In On GRAIL

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp grew its holdings in GRAIL by 15,733.3% during the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new position in GRAIL during the fourth quarter valued at approximately $26,000. Comerica Bank grew its holdings in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in GRAIL during the fourth quarter valued at approximately $28,000. Finally, Elyxium Wealth LLC acquired a new position in GRAIL during the fourth quarter valued at approximately $31,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.